Long-term Effects of WISE Program Improving Frailty Status and Quality of Life for Adolescents With CHD
Key facts
- Who runs it
- National Yang Ming Chiao Tung University
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Jul 2023
- Ended
- 30 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- with WISE (Walking Instruction based on Self-Efficacy)
- without WISE (Walking Instruction based on Self-Efficacy)
- Record updated
- 22 March 2024
- Why it stopped
- Based on our previous investigations, we've decided to construct a scale first.
Who can take part
- Age
- 12 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Aged between 12-18 years old
- Congenital heart disease diagnosed by a doctor before the age of 2
- The American New York Heart Association (NYHA) classifies the cardiac function as I-III grades
- Adolescents and their parents or guardians can communicate in Mandarin and Taiwanese and have normal cognitive abilities
- Those who are willing to cooperate with the research and complete the consent form
Who cannot take part
- Received a heart transplant within one year
- Have undergone open-heart surgery within six months
- The New York Heart Association (NYHA) classifies the cardiac function as class IV
- Combined with other congenital diseases
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Most children with congenital heart disease (CHD) are expected to survive until adulthood. In addition to physical limitations, the growing adolescents with CHD are also challenged at the psychosocial domains. Previous studies have investigated the frailty of elderly, but the research on the intervention to the frailty of adolescents with CHD has been limited. The aims of this study will apply the Walking Instruction based on Self-Efficacy (WISE) program to examine the long-term effects of improving frailty state and quality of life for adolescents with CHD.
The 2 groups in the trial
- Experimental - with WISETreatment being tested
The experimental group will provide walking health education leaflets and exercise measurement wristbands for exercise monitoring, and will be given the intervention of the WISE program: three times a week, each time walking for at least 30 minutes, with a pace between 100-130 steps/ minutes, and then increase the number or time weekly according to personal ability.
Treatment: with WISE (Walking Instruction based on Self-Efficacy)
- Control - without WISEExisting treatment, for comparison
The procedure of the control group will be the same as that of the experimental group, providing walking and health education leaflets and exercise measurement wristbands for exercise monitoring, but no intervention in the WISE program.
Treatment: without WISE (Walking Instruction based on Self-Efficacy)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-term Effects of WISE Program Improving Frailty Status and Quality of Life for Adolescents With Congenital Heart Disease
- Record updated
- 22 March 2024